JGC
BCRX icon

J. Goldman & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

J. Goldman & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-143,500
Closed -$493K – 375
2020
Q3 		$493K Buy
+143,500
New +$615K 0.03% 252

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

J. Goldman & Co's BCRX Position: Q2 2022 in Review

J. Goldman & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 67,306 shares — an estimated $1.09M sold.

J. Goldman & Co first reported a position in BCRX in Q2 2020 and held it in 3 quarters. The position peaked at $1.72M in Q2 2020. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • J. Goldman & Co reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • J. Goldman & Co sold 67,306 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $1.09M.
  • J. Goldman & Co first reported a position in BioCryst Pharmaceuticals in Q2 2020 and held it in 3 quarters.
  • J. Goldman & Co's BioCryst Pharmaceuticals position peaked at $1.72M in Q2 2020.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on J. Goldman & Co's 13F filing for Q2 2022, filed 15 Aug 2022.